间充质干细胞及其外泌体在移植中的应用进展  

Application progress of mesenchymal stem cells and their exosomes in allotransplantation

作　　者：邱煜程 周显玉[1] 刘菲[1] 杨军[1] QIU Yucheng;ZHOU Xianyu;LIU Fei;YANG Jun(Department of Plastic and Reconstructive Surgery,Shanghai Ninth People’s Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200011,China)

机构地区：[1]上海交通大学医学院附属第九人民医院整复外科,上海市200011

出　　处：《组织工程与重建外科》2023年第2期184-188,共5页Journal of Tissue Engineering and Reconstructive Surgery

基　　金：国家自然科学基金(81871576);上海市临床重点专科建设项目—整形外科(shslczdzk00901);上海市科委项目(上海市整形与修复重建临床医学研究中心,22MC1940300)。

摘　　要：无论是实体器官移植(Solid organ transplantation,SOT)还是同种异体复合组织移植(Vascularized composite allotransplantation,VCA),患者都需要接受长期的免疫抑制治疗,不仅会引发各种脏器的毒副反应,还可能威胁生命安全。间充质干细胞及其外泌体已被证实有助于控制急性排斥反应和诱导免疫耐受。本文对间充质干细胞及其外泌体在SOT和VCA中的应用现状进行综述。Long term administration of immunosuppressive therapies is required in solid organ transplantation(SOT)and vascularized composite allotransplantation(VCA).However,medication of combined immunosuppressants will result in multiple organ toxicities,and even threaten lives.Mesenchymal stem cells and their exosomes are proved to be effective to control acute allograft rejection and induce tolerance as a cell therapy.In this paper,the mesenchymal stem cells and their exosomes in SOT and VCA were reviewed.

关 键 词：间充质干细胞 外泌体 免疫抑制治疗 实体器官移植 同种异体复合组织移植 

分 类 号：R979.5[医药卫生—药品]